In part 1 of this Exclusive Interview, Jon Odorico talks with Diabetes in Control during the ADA 2018 convention in Orlando about advances in the work on stem cell-derived beta cells.
Jon Odorico MD is Director of the Pancreas and Islet Cell Transplantation Programs and Professor in the Department of Surgery, Division of Organ Transplantation at the University of Wisconsin-Madison School of Medicine and Public Health.
Transcript of this video segment:
Odorico: John Odorico, Professor of Surgery at the University of Wisconsin, Madison School of Medicine and Public Health.
What recent advances have been achieved in the stem cell derived beta cells arena? A number of them over the last few years. Firstly, in 2014, some very important publications which showed improved differentiation of the cells through an in vitro protocol to getting to more phenotypically and functionally mature beta cells.
In addition, there have been some important encapsulation advances too. In the field of micro- and macro-encapsulation – delivering better oxygen and having better survival of the cells.
Many of the recent advances were discussed and presented at a recent stem cell meeting in Boston where 170 delegates were brought together from a dozen countries at a stem cell-derived beta cell Key Opinions Leaders Meeting sponsored by the International Pancreas and Islet Transplant Association, the Transplantation Society, JDRF (Juvenile Diabetes Research Foundation), and the Harvard Stem Cell Institute; some real exciting advances were presented at that conference last month.